30 related articles for article (PubMed ID: 2907646)
1. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
Wetzel H; Hillert A; Gründer G; Benkert O
Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
3. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
Brusa L; Orlacchio A; Moschella V; Iani C; Bernardi G; Mercuri NB
Mov Disord; 2009 Jan; 24(1):126-9. PubMed ID: 19170197
[TBL] [Abstract][Full Text] [Related]
4. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
Ohmori T; Koyama T; Inoue T; Matsubara S; Yamashita I
Biol Psychiatry; 1993 May; 33(10):687-93. PubMed ID: 8102551
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic properties of (-)-3PPP (preclamol) in man.
Tamminga CA; Cascella NG; Lahti RA; Lindberg M; Carlsson A
J Neural Transm Gen Sect; 1992; 88(3):165-75. PubMed ID: 1358119
[TBL] [Abstract][Full Text] [Related]
6. Dopamine autoreceptor agonists in the treatment of schizophrenic disorders.
Wetzel H; Benkert O
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jul; 17(4):525-40. PubMed ID: 8103233
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical Improvement of Schizophrenic Symptoms by a Dopaminergic Agonist: An Example of Personalized Psychiatry in a Copy Number Variation-Carrying Patient.
Alexandre C; Chaumette B; Martinez G; Christa L; Dupont JM; Kebir O; Gaillard R; Amado I; Krebs MO
Biol Psychiatry; 2016 Aug; 80(4):e21-e23. PubMed ID: 26602590
[No Abstract] [Full Text] [Related]
8. Effects of verapamil administration on negative symptoms of chronic schizophrenia.
Uhr SB; Jackson K; Berger PA; Csernansky JG
Psychiatry Res; 1988 Mar; 23(3):351-2. PubMed ID: 3387506
[No Abstract] [Full Text] [Related]
9. Mechanisms of action of atypical antipsychotic drugs: a critical analysis.
Kinon BJ; Lieberman JA
Psychopharmacology (Berl); 1996 Mar; 124(1-2):2-34. PubMed ID: 8935797
[TBL] [Abstract][Full Text] [Related]
10. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.
Möller HJ; van Praag HM; Aufdembrinke B; Bailey P; Barnes TR; Beck J; Bentsen H; Eich FX; Farrow L; Fleischhacker WW
Psychopharmacology (Berl); 1994 Jun; 115(1-2):221-8. PubMed ID: 7862898
[TBL] [Abstract][Full Text] [Related]
11. The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study.
Gerbaldo H; Demisch L; Lehmann CO; Bochnik J
Pharmacopsychiatry; 1988 Nov; 21(6):387-8. PubMed ID: 2907646
[No Abstract] [Full Text] [Related]
12. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.
Olbrich R; Schanz H
Pharmacopsychiatry; 1988 Nov; 21(6):389-90. PubMed ID: 2907647
[No Abstract] [Full Text] [Related]
13. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
[No Abstract] [Full Text] [Related]
14. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Silver H; Geraisy N
Biol Psychiatry; 1995 Sep; 38(6):413-5. PubMed ID: 8547463
[No Abstract] [Full Text] [Related]
15. B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia.
Wiedemann K; Benkert O; Holsboer F
Pharmacopsychiatry; 1990 Jan; 23(1):50-5. PubMed ID: 1969167
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
